Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;78(8):1015-1018.
doi: 10.1136/annrheumdis-2018-213654. Epub 2018 Oct 8.

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?

Stefan Siebert  1 , Neal L Millar  1 , Iain B McInnes  2
Affiliations
Editorial

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?

Stefan Siebert et al. Ann Rheum Dis. 2019 Aug.
No abstract available

Keywords: DMARDs (biologic); cytokines; spondyloarthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SS has received honoraria or research funding to his University from Novartis, Celgene, Janssen, Pfizer, AbbVie, UCB and Boehringer Ingelheim. NM has received honoraria or research funding to his University from Novartis and Stryker. IBM has received honoraria or research funding to his University from Novartis, Celgene, Janssen, Pfizer, AbbVie, UCB and Boehringer Ingelheim.

Figures

Figure 1
Figure 1
Proposed notional emerging tissue cytokine hierarchy based on current clinical trial data. There is now increasing evidence suggesting that different cytokines may enjoy distinct hierarchical roles in tissues across the spondyloarthritis spectrum. This figure highlights those pathways with demonstrable effects in each discrete tissues against those in which clinical responses were not observed. In the absence of formal head-to-head studies, these comparators should be taken as potential rather than proven. Future analyses are now required to ascribe formal within-tissue hierarchies.
Figure 2
Figure 2
Potential cytokine pathways driving IL-17 responses in spondyloarthritis.
See this image and copyright information in PMC

Comment on

References

    1. Langley RG, Elewski BE, Lebwohl M, et al. . Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 2014;371:326–38. 10.1056/NEJMoa1314258 - DOI - PubMed
    1. Griffiths CE, Reich K, Lebwohl M, et al. . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386:541–51. 10.1016/S0140-6736(15)60125-8 - DOI - PubMed
    1. Blauvelt A, Papp KA, Griffiths CE, et al. . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017;76:405–17. 10.1016/j.jaad.2016.11.041 - DOI - PubMed
    1. Reich K, Papp KA, Blauvelt A, et al. . Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017;390:276–88. 10.1016/S0140-6736(17)31279-5 - DOI - PubMed
    1. Papp KA, Blauvelt A, Bukhalo M, et al. . Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 2017;376:1551–60. 10.1056/NEJMoa1607017 - DOI - PubMed